Y-mabs closes deals in China and Europe for the firm's two drugs against pediatric cancer

According to these new deals, Y-mabs will pass on responsibility for the distribution of its drugs danyelza and omburtamab in China and Europe – the task will instead be passed onto various partners.
Photo: Kelly Davidson Photography
Photo: Kelly Davidson Photography
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

The Danish but US-listed biotech firm Y-mabs has entered two new partnerships in China and Eastern Europe, respectively.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading